• Research/Demonstration Project: France is home to the IPERGAY study, which showed in 2015 that “on-demand” or “intermittent” PrEP (two Truvada tablets taken up to 24 hours before sex, one tablet 24 hours and another 48 hours after sex) could be protective against HIV. ANRS (The French National Research Organization) is currently conducting implementation research into the efficacy of PrEP rollout.
  • Drug Registration: In November 2015, the French National Agency for Medicines and Health Products Safety (ANSM) approved Truvada as PrEP. ANSM’s authorization enabled PrEP use under an RTU (Recommendation of Temporary Use)—the provision of drugs for urgent and off-label use for up to three years. The approval places France as the second country after the US to approve Truvada as PrEP. Truvada had been previously approved only for treatment in France.
  • Policy/Regulatory: In January 2016, full reimbursement by France’s health system became available for Truvada as PrEP, along with counselling and follow-up. Daily PrEP can now be prescribed for anyone assessed as needing it or intermittent PrEP is available for MSM, as studied in the IPERGAY trial. For now, PrEP prescribing is only available from HIV specialist physicians within a hospital clinic or HIV testing site. Many clinics are currently offering PrEP. Information about the nearest clinic is available here.
  • Advocacy: The ASO, AIDES, has led civil society’s advocacy, pushing for regulatory approval and guidelines for rollout. The activist group, Nous Sommes PrEP, is working toward PrEP visibility and the ACT UP Paris website is a good source of PrEP information in France.

Last updated on September 1, 2017.

News Spotlight